A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis

High dose interferon treatment for 1 year is the only established treatment for chronic hepatitis D, but it is associated with a high relapse rate after treatment discontinuation. In this study, patients were treated with 10 MU interferon alpha 2b, thrice weekly for 2 years. Twenty‐three patients we...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2007-11, Vol.14 (11), p.812-816
Main Authors: Yurdaydın, C., Bozkaya, H., Karaaslan, H., Önder, F. O., Erkan, Ö. E., Yalçın, K., Değertekin, H., Bozdayı, A. M., Uzunalimoğlu, Ö.
Format: Article
Language:English
Subjects:
Adult
Alanine Transaminase - blood
Antiviral Agents - therapeutic use
Biopsy
chronic delta hepatitis
Female
Hepatitis D - drug therapy
Hepatitis D - enzymology
Hepatitis D - pathology
Hepatitis D - virology
Hepatitis D virus
Hepatitis Delta Virus - growth & development
Histocytochemistry
Humans
Interferon-alpha - therapeutic use
Male
Pilot Projects
Recombinant Proteins
Reverse Transcriptase Polymerase Chain Reaction
RNA, Viral - blood
RNA, Viral - chemistry
RNA, Viral - genetics
treatment
two years of interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High dose interferon treatment for 1 year is the only established treatment for chronic hepatitis D, but it is associated with a high relapse rate after treatment discontinuation. In this study, patients were treated with 10 MU interferon alpha 2b, thrice weekly for 2 years. Twenty‐three patients were recruited and 15 completed the 2‐year treatment and 6 months follow‐up periods. Treatment response was assessed biochemically [normal alanine aminotransferase (ALT)], virologically (undetectable hepatitis D virus RNA) and histologically (at least 2 point decrease in the Knodell score) at the end of treatment (EOT) and at the end of follow‐up. Out of 15 patients who finished the 2‐year treatment period, seven patients (47%) had a biochemical response but only two (13%) had a normal ALT after follow‐up. ALT decreased from the baseline value of 143.1 ± 121.7 (mean ± SD) to 39.7 ± 20.6 (P 
ISSN:1352-0504
1365-2893
DOI:10.1111/j.1365-2893.2007.00875.x